메뉴 건너뛰기
Journal of Clinical Oncology
Volumn 27, Issue 1, 2009, Pages 156-157
Erythema multiforme/stevens-johnson syndrome/toxic epidermal necrolysis in lenalidomide-treated patients
Author keywords

[No Author keywords available]
Indexed keywords

ALENDRONIC ACID; ALLOPURINOL; BORTEZOMIB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; IMATINIB; LENALIDOMIDE; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLONE DERIVATIVE; RITUXIMAB; TAMOXIFEN; THALIDOMIDE; TRIMETHOPRIM;
EID: 58149343983     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.3737     Document Type: Letter
Times cited : (30)
References (8)
  • 1
    • 17444381936 scopus 로고    scopus 로고
    • Stevens-Johnson syndrome and toxic epidermal necrolysis: A review of the literature
    • Letko GN, Papaliodis DN, Papaliodis GN, et al: Stevens-Johnson syndrome and toxic epidermal necrolysis: A review of the literature. Annals Allergy Asthma Immunol 94:419-436, 2007
    • (2007) Annals Allergy Asthma Immunol , vol.94 , pp. 419-436
    • Letko, G.N.1    Papaliodis, D.N.2    Papaliodis, G.N.3
  • 2
    • 0031473611 scopus 로고    scopus 로고
    • Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme
    • Roujeau JC: Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme. J Dermatol 24(11):726-729, 1997
    • (1997) J Dermatol , vol.24 , Issue.11 , pp. 726-729
    • Roujeau, J.C.1
  • 3
    • 0028880443 scopus 로고
    • Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis
    • Roujeau JC, Kelly JP, Naldi L, et al: Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 333:1600-1606, 1995
    • (1995) N Engl J Med , vol.333 , pp. 1600-1606
    • Roujeau, J.C.1    Kelly, J.P.2    Naldi, L.3
  • 4
    • 37049020666 scopus 로고    scopus 로고
    • Stevens-Johnson syndrome and toxic epidermal necrolysis: Assessment of medication risks with emphasis on recently marketed drugs-The EuroSCAR study
    • Mockenhaupt M, Viboud C, Dunant A, et al: Stevens-Johnson syndrome and toxic epidermal necrolysis: Assessment of medication risks with emphasis on recently marketed drugs-The EuroSCAR study. J Invest Dermatol 128:35-44, 2008
    • (2008) J Invest Dermatol , vol.128 , pp. 35-44
    • Mockenhaupt, M.1    Viboud, C.2    Dunant, A.3
  • 5
    • 0036929546 scopus 로고    scopus 로고
    • Stevens-Johnson syndrome after treatment with rituximab
    • Lowndes S, Darby A, Mead G, et al: Stevens-Johnson syndrome after treatment with rituximab. Ann Oncol 13:1948-1950, 2002
    • (2002) Ann Oncol , vol.13 , pp. 1948-1950
    • Lowndes, S.1    Darby, A.2    Mead, G.3
  • 6
    • 0344987882 scopus 로고    scopus 로고
    • Severe skin reaction to imatinib in a case of Philadelphia-positive lymphoblastic leukemia
    • Sanchez-Gonzalez B, Pascual-Ramirez, Fernandez-Abellan P, et al: Severe skin reaction to imatinib in a case of Philadelphia-positive lymphoblastic leukemia. Blood 101:2446, 2003
    • (2003) Blood , vol.101 , pp. 2446
    • Sanchez-Gonzalez, B.1    Pascual-Ramirez, F.-A.P.2
  • 7
    • 34548697755 scopus 로고    scopus 로고
    • Severe epidermal necrolysis after bortezomib treatment for multiple myeloma
    • Fang B, Song Y, Ma J, et al: Severe epidermal necrolysis after bortezomib treatment for multiple myeloma. Acta Haematol 118:65-67, 2007
    • (2007) Acta Haematol , vol.118 , pp. 65-67
    • Fang, B.1    Song, Y.2    Ma, J.3
  • 8
    • 33750074147 scopus 로고    scopus 로고
    • Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma
    • Svigguni H, Davis M, Rajkumar V, et al: Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. Arch Dermatol 142:1298-1302, 2006
    • (2006) Arch Dermatol , vol.142 , pp. 1298-1302
    • Svigguni, H.1    Davis, M.2    Rajkumar, V.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.